In vitro fertilization (IVF) is a form of assisted reproductive technology in which a woman’s reproductive system is artificially stimulated to produce oocytes, which are extracted, fertilized in a laboratory, and then implanted in the uterus. This is a multistep process that needs to be carefully controlled with the use of medications due to the complex interplay of the various drugs used to replicate the different stages of the fertilization process by IVF healthcare team. IVF is a multistep process involving ovarian stimulation, ovulation induction, collection of oocytes, fertilization with sperm, and transfer of the fertilized oocytes to the uterus for implantation and maturation by following various stages. At each stage, there are different protocols for the use of these drugs, and the most appropriate pharmacologic regimen and therapeutic intervention are chosen after a thorough pre-treatment evaluation and an accurate diagnosis, controlled ovarian stimulation is achieved with the use of gonadotropin-releasing hormone (GnRH) analogues and inhibitors of natural steroid hormones, such as clomiphene citrate, recombinant follicle-stimulating hormone (FSH), and luteinizing hormone (LH) and also by providing food supplements to patients, such as Coenzyme Q10 (CoQ10) and DHEA are two supplements that are often used to help older women (over 35) and those with limited ovarian reserve. These are commonly used by women who are undergoing IVF to boost the number of eggs generated by their ovaries.
Market Dynamics
Key players and market players operating in the market are focusing on expanding and developing efficient IVF facilities which can be attributed to the growth of the UAE IVF drugs and food supplements market. For instance, on November 14, 2021, Mediclinic Middle East, which is a part of Mediclinic International and hospital group that operates seven hospitals in the UAE announced the 100% acquisition of Bourn Hall Fertility Centre, an IVF specialties center in the MENA region from TVM Capital Healthcare, following an initial acquisition of 30% of the shares in December 2018.The aim of this acquisition is to provide the highest level of quality care with exceptional outcomes through this acquisition to provide better services for IVF facilities.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Detailed Segmentation:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients